We have located links that may give you full text access.
Novel presentation of a feline patient with visceral and cervical lymph node hemangiosarcoma.
OBJECTIVE: To report a novel presentation of feline hemangiosarcoma.
ANIMALS: A 14-year-old spayed female feline patient diagnosed with hemangiosarcoma of the spleen and a cervical lymph node.
CLINICAL PRESENTATION, PROGRESSION, AND PROCEDURES: The patient presented to the emergency service following a 1-week history of lethargy and hiding. Abdominal ultrasound revealed splenomegaly with multiple nodules and peritoneal fluid that was consistent with hemorrhagic effusion.
TREATMENT AND OUTCOME: The patient underwent a routine splenectomy and was started on doxorubicin. Histopathologic evaluation of the spleen confirmed visceral hemangiosarcoma. When the disease showed signs of progression, combination chemotherapy with cyclophosphamide and vincristine was initiated. Four months following presentation, a submandibular lymph node was removed and found to have metastatic hemangiosarcoma. From presentation to euthanasia, the patient survived 205 days.
CLINICAL RELEVANCE: Hemangiosarcoma is a rare cancer in feline patients, with a lack of veterinary literature on its presentation and chemotherapy protocols. The subject of this case report had a novel presentation of hemangiosarcoma and responded favorably to a chemotherapy protocol not previously described for this disease.
ANIMALS: A 14-year-old spayed female feline patient diagnosed with hemangiosarcoma of the spleen and a cervical lymph node.
CLINICAL PRESENTATION, PROGRESSION, AND PROCEDURES: The patient presented to the emergency service following a 1-week history of lethargy and hiding. Abdominal ultrasound revealed splenomegaly with multiple nodules and peritoneal fluid that was consistent with hemorrhagic effusion.
TREATMENT AND OUTCOME: The patient underwent a routine splenectomy and was started on doxorubicin. Histopathologic evaluation of the spleen confirmed visceral hemangiosarcoma. When the disease showed signs of progression, combination chemotherapy with cyclophosphamide and vincristine was initiated. Four months following presentation, a submandibular lymph node was removed and found to have metastatic hemangiosarcoma. From presentation to euthanasia, the patient survived 205 days.
CLINICAL RELEVANCE: Hemangiosarcoma is a rare cancer in feline patients, with a lack of veterinary literature on its presentation and chemotherapy protocols. The subject of this case report had a novel presentation of hemangiosarcoma and responded favorably to a chemotherapy protocol not previously described for this disease.
Full text links
Related Resources
Trending Papers
Consensus Statement on Vitamin D Status Assessment and Supplementation: Whys, Whens, and Hows.Endocrine Reviews 2024 April 28
The Tricuspid Valve: A Review of Pathology, Imaging, and Current Treatment Options: A Scientific Statement From the American Heart Association.Circulation 2024 April 26
Intravenous infusion of dexmedetomidine during the surgery to prevent postoperative delirium and postoperative cognitive dysfunction undergoing non-cardiac surgery: a meta-analysis of randomized controlled trials.European Journal of Medical Research 2024 April 19
Interstitial Lung Disease: A Review.JAMA 2024 April 23
Ventilator Waveforms May Give Clues to Expiratory Muscle Activity.American Journal of Respiratory and Critical Care Medicine 2024 April 25
Acute Kidney Injury and Electrolyte Imbalances Caused by Dapagliflozin Short-Term Use.Pharmaceuticals 2024 March 27
Systemic lupus erythematosus.Lancet 2024 April 18
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app